Management of patients with castration-resistant disease.

@article{Pezaro2013ManagementOP,
  title={Management of patients with castration-resistant disease.},
  author={Carmel Pezaro and Aurelius Gabriel Omlin and David S{\'a}nchez Lorente and Johann S de Bono},
  journal={Hematology/oncology clinics of North America},
  year={2013},
  volume={27 6},
  pages={
          1243-60, ix
        }
}
The medical management of men with castration-resistant prostate cancer (CRPC) has changed dramatically in the last decade. Men can now access several agents developed to extend survival, delay morbidity caused by complications, and preserve quality of life. Strategies to extend survival include docetaxel and cabazitaxel, the CYP-inhibitor abiraterone acetate, the second-generation androgen receptor antagonist enzalutamide, sipuleucel-T immunotherapy, and the α-emitting radionuclide (223)radium… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 76 REFERENCES

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

HI Scher, X Jia, JS de Bono
  • Lancet Oncol
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

HI Scher, X Jia, JS de Bono
  • Lancet Oncol
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)

DE Rathkopf, MJ Morris, DC Danila
  • J Clin Oncol
  • 2012
VIEW 1 EXCERPT

ARMOR1: safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naı̈ve patients with castration resistant Management of CRPC 1257 prostate cancer (CRPC)

ME Taplin, F Chu, JP Morrison
  • AACR Annual Meeting. Chicago;
  • 2012
VIEW 1 EXCERPT

ARMOR1: safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naı̈ve patients with castration resistant Management of CRPC 1257 prostate cancer (CRPC)

ME Taplin, F Chu, JP Morrison
  • AACR Annual Meeting. Chicago;
  • 2012
VIEW 1 EXCERPT